Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Intervalo de año de publicación
1.
Cells ; 9(9)2020 09 18.
Artículo en Inglés | MEDLINE | ID: mdl-32961896

RESUMEN

Pulmonary arterial hypertension (PAH) is characterized by the remodeling of pulmonary arteries, with an increased pulmonary arterial pressure and right ventricle (RV) overload. This work investigated the benefit of the association of human umbilical cord mesenchymal stem cells (hMSCs) with lodenafil, a phosphodiesterase-5 inhibitor, in an animal model of PAH. Male Wistar rats were exposed to hypoxia (10% O2) for three weeks plus a weekly i.p. injection of a vascular endothelial growth factor receptor inhibitor (SU5416, 20 mg/kg, SuHx). After confirmation of PAH, animals received intravenous injection of 5.105 hMSCs or vehicle, followed by oral treatment with lodenafil carbonate (10 mg/kg/day) for 14 days. The ratio between pulmonary artery acceleration time and RV ejection time reduced from 0.42 ± 0.01 (control) to 0.24 ± 0.01 in the SuHx group, which was not altered by lodenafil alone but was recovered to 0.31 ± 0.01 when administered in association with hMSCs. RV afterload was confirmed in the SuHx group with an increased RV systolic pressure (mmHg) of 52.1 ± 8.8 normalized to 29.6 ± 2.2 after treatment with the association. Treatment with hMSCs + lodenafil reversed RV hypertrophy, fibrosis and interstitial cell infiltration in the SuHx group. Combined therapy of lodenafil and hMSCs may be a strategy for PAH treatment.


Asunto(s)
Antihipertensivos/farmacología , Carbonatos/farmacología , Hipertensión Pulmonar/terapia , Hipertrofia Ventricular Derecha/terapia , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas/citología , Inhibidores de Fosfodiesterasa 5/farmacología , Piperazinas/farmacología , Pirimidinas/farmacología , Administración Oral , Animales , Terapia Combinada/métodos , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5/genética , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5/metabolismo , Modelos Animales de Enfermedad , Humanos , Hipertensión Pulmonar/genética , Hipertensión Pulmonar/metabolismo , Hipertensión Pulmonar/fisiopatología , Hipertrofia Ventricular Derecha/genética , Hipertrofia Ventricular Derecha/metabolismo , Hipertrofia Ventricular Derecha/fisiopatología , Hipoxia/genética , Hipoxia/metabolismo , Hipoxia/fisiopatología , Hipoxia/terapia , Indoles/farmacología , Masculino , Células Madre Mesenquimatosas/fisiología , Arteria Pulmonar/efectos de los fármacos , Arteria Pulmonar/metabolismo , Arteria Pulmonar/fisiopatología , Pirroles/farmacología , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Resultado del Tratamiento , Cordón Umbilical/citología , Cordón Umbilical/fisiología , Receptor 2 de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Receptor 2 de Factores de Crecimiento Endotelial Vascular/genética , Receptor 2 de Factores de Crecimiento Endotelial Vascular/metabolismo
2.
Cien Saude Colet ; 18(7): 2075-84, 2013 Jul.
Artículo en Portugués | MEDLINE | ID: mdl-23827912

RESUMEN

The scope of this study was to evaluate the effects of a public program of application of botulinum toxin type A (BoNT-A) in terms of muscle spasticity, range of motion, quality of gait, functional independence and quality of life of children and adolescents with cerebral palsy (CP). A quasi-experimental study was conducted with 14 children with CP to evaluate the effects of three applications of BoNT-A, at intervals of three months. Children were assessed using the Modified Ashworth Rating Scale, the Manual Goniometer, the Physician Rating Scale, the Pediatric Evaluation of Disability Inventory (PEDI) and the Caregiver Questionnaire (CQ). There was a reduction of spasticity, an increase in the range of motion, an improvement of the functional abilities of self-care and mobility of PEDI and the areas of personal care, comfort and interaction/communication with the CQ. The BoNT-A application program for children and adolescents with CP, conducted in a public rehabilitation service in the Jequitinhonha Valley, was effective for the targeted population.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Parálisis Cerebral/complicaciones , Espasticidad Muscular/tratamiento farmacológico , Espasticidad Muscular/etiología , Fármacos Neuromusculares/uso terapéutico , Adolescente , Brasil , Niño , Preescolar , Evaluación de la Discapacidad , Femenino , Humanos , Masculino , Evaluación de Programas y Proyectos de Salud
3.
Ciênc. Saúde Colet. (Impr.) ; 18(7): 2075-2084, Jul. 2013. graf, tab
Artículo en Portugués | LILACS | ID: lil-679607

RESUMEN

O objetivo do estudo foi avaliar os efeitos de um programa público de aplicação de toxina botulínica tipo A (TBA) na espasticidade muscular, amplitude de movimento, qualidade da marcha, independência funcional e qualidade de vida de crianças e adolescentes com paralisia cerebral (PC). Foi realizado um estudo quase experimental que avaliou os efeitos do emprego da TBA, aplicada três vezes, com intervalos de três meses, em 14 crianças com PC. Estas foram avaliadas através da Escala Modificada de Ashworth, Goniometria Manual, Physician Rating Scale, Inventário de Avaliação Pediátrica de Incapacidade (PEDI) e Questionário do Cuidador da Criança (QCC). Foi observada redução da espasticidade, aumento da amplitude de movimento, melhora das habilidades funcionais de autocuidado e mobilidade do PEDI e das áreas de cuidado pessoal, conforto e interação/comunicação do QCC. O programa de aplicação de TBA em crianças e adolescentes com PC, realizado em um núcleo de reabilitação público do Vale do Jequitinhonha, foi efetivo para a população beneficiada.


The scope of this study was to evaluate the effects of a public program of application of botulinum toxin type A (BoNT-A) in terms of muscle spasticity, range of motion, quality of gait, functional independence and quality of life of children and adolescents with cerebral palsy (CP). A quasi-experimental study was conducted with 14 children with CP to evaluate the effects of three applications of BoNT-A, at intervals of three months. Children were assessed using the Modified Ashworth Rating Scale, the Manual Goniometer, the Physician Rating Scale, the Pediatric Evaluation of Disability Inventory (PEDI) and the Caregiver Questionnaire (CQ). There was a reduction of spasticity, an increase in the range of motion, an improvement of the functional abilities of self-care and mobility of PEDI and the areas of personal care, comfort and interaction/communication with the CQ. The BoNT-A application program for children and adolescents with CP, conducted in a public rehabilitation service in the Jequitinhonha Valley, was effective for the targeted population.


Asunto(s)
Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Toxinas Botulínicas Tipo A/uso terapéutico , Parálisis Cerebral/complicaciones , Espasticidad Muscular/tratamiento farmacológico , Espasticidad Muscular/etiología , Fármacos Neuromusculares/uso terapéutico , Brasil , Evaluación de la Discapacidad , Evaluación de Programas y Proyectos de Salud
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...